Business
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
MENLO PARK, Calif., April 30, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York.
About this update from An2 Therapeutics, Inc.
MENLO PARK, Calif., April 30, 2025 --( BUSINESS WIRE )--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York. Details of the event is as follows: Citizens JMP Life Sciences Conference A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com . An archived replay will be available for at least 30 days. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20250430523287/en/ Contacts COMPANY CONTACT: Lucy O. Day Chief Financial Officer [email protected] INVESTOR AND MEDIA CONTACT: Anne Bowdidge [email protected]
View stock analysis, news, and events for An2 Therapeutics, Inc.